Arcus Biosciences (NYSE:RCUS) Stock Rating Reaffirmed by Mizuho

Arcus Biosciences (NYSE:RCUS – Get Rating)‘s stock had its “buy” rating reiterated by analysts at Mizuho in a research note issued on Friday, Benzinga reports. They currently have a $51.00 price objective on the stock. Mizuho’s target price points to a potential upside of 210.03% from the stock’s previous close.

Other research analysts have also recently issued research reports about the stock. TheStreet cut shares of Arcus Biosciences from a “c-” rating to a “d” rating in a research note on Tuesday, February 28th. Barclays cut their target price on shares of Arcus Biosciences from $60.00 to $36.00 and set an “overweight” rating for the company in a research note on Wednesday, December 21st. Citigroup cut their target price on shares of Arcus Biosciences from $42.00 to $40.00 in a research note on Thursday, March 9th. Finally, Bank of America assumed coverage on shares of Arcus Biosciences in a research note on Friday, November 18th. They issued a “neutral” rating and a $33.00 target price for the company. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, Arcus Biosciences has an average rating of “Moderate Buy” and an average target price of $41.33.

Arcus Biosciences Trading Down 3.0 %

NYSE:RCUS opened at $16.45 on Friday. Arcus Biosciences has a 1 year low of $15.70 and a 1 year high of $39.75. The firm has a 50 day moving average of $19.52 and a 200-day moving average of $24.06. The stock has a market capitalization of $1.20 billion, a P/E ratio of -4.42 and a beta of 0.89.

Institutional Trading of Arcus Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in RCUS. MetLife Investment Management LLC raised its position in shares of Arcus Biosciences by 57.4% during the 1st quarter. MetLife Investment Management LLC now owns 25,039 shares of the company’s stock valued at $790,000 after acquiring an additional 9,127 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Arcus Biosciences by 77.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 437,969 shares of the company’s stock valued at $13,826,000 after acquiring an additional 190,527 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Arcus Biosciences by 2.5% during the 1st quarter. Vanguard Group Inc. now owns 3,512,114 shares of the company’s stock valued at $110,843,000 after acquiring an additional 85,778 shares during the last quarter. Ergoteles LLC bought a new stake in shares of Arcus Biosciences during the 1st quarter valued at $1,261,000. Finally, Lazard Asset Management LLC acquired a new position in shares of Arcus Biosciences in the 1st quarter valued at $76,000. Institutional investors own 72.97% of the company’s stock.

About Arcus Biosciences

(Get Rating)

Arcus Biosciences, Inc engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.